Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
Crossref DOI link: https://doi.org/10.1007/s00228-017-2226-2
Published Online: 2017-03-06
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lee, Sun Ku
Xing, Jun
Catlett, Ian M.
Adamczyk, Robert
Griffies, Amber
Liu, Ang
Murthy, Bindu
Nowak, Miroslawa
Funding for this research was provided by:
Bristol-Myers Squibb Research and Development
License valid from 2017-03-06